Nilo Azad, MD

Articles

Unmet Needs in Third-Line mCRC: Challenges and Opportunities

December 12th 2024

Panelists discuss the most significant unmet needs in treating third-line metastatic colorectal cancer (mCRC), highlight areas where additional research is needed to improve patient outcomes, and explore investigational agents they find promising for future treatment options.

Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment

December 12th 2024

Panelists discuss the frequency of hypertension observed with trifluridine-tipiracil plus bevacizumab and their strategies for monitoring and managing it, as well as their approach to dosing TAS-102 plus bevacizumab in patients with hepatic or renal impairment. They also review common toxicities associated with fruquintinib and regorafenib, including hypertension, hand-foot syndrome, and hepatotoxicity, and share management strategies for these adverse events.

Navigating Toxicities: Trifluridine-Tipiracil Plus Bevacizumab

December 5th 2024

Panelists discuss the common toxicities associated with trifluridine-tipiracil plus bevacizumab in clinical practice, including their typical severity, and share their strategies for managing dose reductions and interruptions due to cytopenias when treating patients with this regimen.

Factoring in Health-Related Quality of Life Outcomes in mCRC Treatment Selection

December 5th 2024

Panelists discuss how health-related quality of life (HRQOL) data influence their treatment decisions for third-line metastatic colorectal cancer (mCRC), how they assess patient symptoms and quality of life in clinical practice, and how the toxicity profiles of different therapies guide their treatment choices.

Perspectives on the SUNLIGHT Trial: Study Design and Outcomes

November 28th 2024

Panelists discuss their perspectives on the SUNLIGHT trial and how its active-arm comparator design, compared with placebo-controlled trials like FRESCO-2 and CORRECT, influences their treatment approach, while also exploring how specific efficacy outcomes impact their decision-making in third-line metastatic colorectal cancer.

Treatment Sequencing in mCRC: Balancing Expert Perspectives and Shared Decision-Making With Patients

November 28th 2024

Panelists discuss how patient preferences and lifestyle factors are considered when selecting between treatment options for third-line metastatic colorectal cancer (mCRC) and speak about their approaches to shared decision-making and optimal sequencing of therapies based on clinical context and patient needs.

Navigating mCRC: Treatment Options in the Third-Line Setting

November 21st 2024

Panelists discuss their preferred treatment options for patients in the third-line setting of metastatic colorectal cancer (mCRC), focusing on regorafenib, trifluridine-tipiracil plus bevacizumab, and fruquintinib, and share insights on how patient and disease-specific factors influence the selection of the most appropriate regimen for each clinical scenario.

Nuances With Defining “Refractory” mCRC in the Third-Line Setting

November 21st 2024

Panelists discuss how “refractory” metastatic colorectal cancer (mCRC) is defined in the third- vs fourth-line setting, and the treatment goals in the third-line setting, focusing on optimizing patient outcomes and managing progression after prior therapies.